Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis

Clinical Cancer Research

Volumn 6, Issue 1, 2000, Pages 153-159

  Salvesen, Helga B ^a,b,c   Das, Soma ^c   Akslen, Lars A ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; NUCLEAR PROTEIN; PROTEIN P16;

ARTICLE; CANCER INVASION; CASE REPORT; DISEASE ASSOCIATION; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; METHYLATION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

AGED; CELL NUCLEUS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GENES, P16; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROMOTER REGIONS (GENETICS); RECEPTORS, ESTRADIOL; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033979559     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Cairns, P., Polascik, T. J., Eby, Y., Tokino, K., Califano, J., Merlo, A., Mao, L., Herath, J., Jenkins, R., Westra, W., Rutter, J. L., Buckler, A., Gabrielson, E., Tockman, M., Cho, K. R., Hedrick, L., Bova, G. S., Isaacs, W., Koch, W., Schwab, D., and Sidransky, D. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat. Genet., 11: 210-212, 1995.
2. INK4 in human cancer. Proc. Natl. Acad. Sci. USA, 91: 11045-11049, 1994.
3. Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., and Skolnick, M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science (Washington DC), 264: 436-440, 1994.
4. Reed, A. L., Califano, J., Cairns, P., Westra, W. H., Jones, R. M., Koch, W., Ahrendt, S., Eby, Y., Sewell, D., Nawroz, H., Bartek, J., and Sidransky, D. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res., 56: 3630-3633, 1996.
5. Muscarella, P., Melvin, W. S., Fisher, W. E., Foor, J., Ellison, E. C., Herman, J. G., Schirmer, W. J., Hitchcock, C. L., DeYoung, B. R., and Weghorst, C. M. Genetic alterations in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors: an analysis of p16/MTS1 tumor suppressor gene inactivation. Cancer Res., 58: 237-240, 1998.
6. Herman, J. G., Merlo, A., Mao, L., Lapidus, R. G., Issa, J. P., Davidson, N. E., Sidransky, D., and Baylin, S. B. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res., 55: 4525-4530, 1995.
7. Merlo, A., Herman, J. G., Mao, L., Lee, D. J., Gabrielson, E., Burger, P. C., Baylin, S. B., and Sidransky, D. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/ CDKN2/MTS1 in human cancers. Nat. Med., 1: 686-692, 1995.
8. Cairns, P., Mao, L., Merlo, A., Lee, D. J., Schwab, D., Eby, Y., Tokino, K., van der Riet, P., Blaugrund, J. E., and Sidransky, D. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science (Washington DC), 265: 415-417, 1994.
9. INK4 expression in nonsmall cell lung carcinoma. Cancer (Phila.), 80: 389-395, 1997.
10. Kawabuchi, B., Moriyama, S., Hironaka, M., Fujii, T., Koike, M., Moriyama, H., Nishimura, Y., Mizuno, S., and Fukayama, M. p16 inactivation in small-sized lung adenocarcinoma: its association with poor prognosis. Int. J. Cancer, 84: 49-53, 1999.
11. Straume, O., and Akslen, L. A. Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma. Int. J. Cancer, 74: 535-539, 1997.
12. Takita, J., Hayashi, Y., Nakajima, T., Adachi, J., Tanaka, T., Yamaguchi, N., Ogawa, Y., Hanada, R., Yamamoto, K., and Yokota, J. The p16 (CDKN2A) gene is involved in the growth of neuroblastoma cells and its expression is associated with prognosis of neuroblastoma patients. Oncogene, 17: 3137-3143, 1998.
13. INK4B alterations in primary gynecologic malignancy. Gynecol. Oncol., 65: 319-324, 1997.
14. Nakashima, R., Fujita, M., Enomoto, T., Haba, T., Yoshino, K., Wada, H., Kurachi, H., Sasaki, M., Wakasa, K., Inoue, M., Buzard, G., and Murata, Y. Alteration of p16 and p15 genes in human uterine tumours. Br. J. Cancer, 80: 458-467, 1999.
15. Peiffer, S. L., Bartsch, D., Whelan, A. J., Mutch, D. G., Herzog, T. J., and Goodfellow, P. J. Low frequency of CDKN2 mutation in endometrial carcinomas. Mol. Carcinog., 13: 210-212, 1995.
16. Hatta, Y., Hirama, T., Takeuchi, S., Lee, E., Pham, E., Miller, C. W., Strohmeyer, T., Wilczynski, S. P., Melmed, S., and Koeffler, H. P. Alterations of the p16 (MTS1) gene in testicular, ovarian, and endometrial malignancies. J. Urol., 154: 1954-1957, 1995.
17. Milde-Langosch, K., Riethdorf, L., Bamberger, A. M., and Löning, T. P16/MTS1 and pRB expression in endometrial carcinomas. Virchows Arch., 434: 23-28, 1999.
18. INK4 in human endometrioid-type endometrial carcinoma. Cancer (Phila.), 80: 2250-2256, 1997.
19. The Cancer Registry of Norway. Cancer in Norway 1992, 1st ed., pp. 60-61. Oslo, Norway: Institute for Epidemiological Cancer Research, 1995.
20. Salvesen, H. B., Iversen, O. E., and Akslen, L. A. Prognostic significance of angiogenesis, Ki-67, p53 and p21 expression: a population-based endometrial carcinoma study. J. Clin. Oncol., 17: 1382-1390, 1999.
21. Salvesen, H. B., Akslen, L. A., Albrektsen, G., and Iversen, O. E. Poorer survival for nulliparous women with endometrial carcinoma. Cancer (Phila.), 82: 1328-1333, 1998.
22. Salvesen, H. B., Iversen, O. E., and Akslen, L. A. Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas. Clin. Cancer Res., 4: 2779-2785, 1998.
23. Salvesen, H. B., Iversen, O. E., and Akslen, L. A. Independent prognostic importance of microvessel density in endometrial carcinoma. Br. J. Cancer, 77: 1140-1144, 1998.
24. INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. Cancer Res., 55: 6006-6011, 1995.
25. Iversen, O. E. Flow cytometric deoxyribonucleic acid index: a prognostic factor in endometrial carcinoma. Am. J. Obstet. Gynecol., 155: 770-776, 1986.
26. Herman, J. G., Graff, J. R., Myohanen, S., Nelkin, B. D., and Baylin, S. B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA, 93: 9821-9826, 1996.
27. Koh, J., Enders, G. H., Dynlacht, B. D., and Harlow, E. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature (Lond.), 375: 506-510, 1995.
28. ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers. Clin. Cancer Res., 5: 791-800, 1999.
29. Møller, M. B., Ino, Y., Gerdes, A. M., Skjødt, K., Louis, D. N., and Pedersen, N. T. Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma. Leukemia (Baltimore), 13: 453-459, 1999.
30. Rose, P. G. Endometrial carcinoma. N. Engl. J. Med., 335: 640-649, 1996.
31. Zaino, R., Kurman, R. J., Diana, K. L., and Morrow, C. P. Pathologic models to predict outcome for women with endometrial carcinoma. Cancer (Phila.), 77: 1115-1121, 1996.
32. Nordström, B., Strang, P., Bergström, R., Nilsson, S., and Tribukait, B. A comparison of proliferation markers and their prognostic value for women with endometrial carcinoma. Cancer (Phila.), 78: 1942-1951, 1996.
33. Ito, K., Watanabe, K., Nasim, S., Sasano, H., Sato, S., Yajima, A., Silverberg, S. G., and Garrett, C. T. Prognostic significance of p53 overexpression in endometrial cancer. Cancer Res., 54: 4667-4670, 1994.
34. Rotman, M., Aziz, H., Halpern, J., Schwartz, D., Sohn, C., and Choi, K. Endometrial carcinoma: influence of prognostic factors on radiation management. Cancer (Phila.), 71: 1471-1479, 1993.